[go: up one dir, main page]

MX9701385A - Preparacion de producto combinado para usarse en enfermedades inmunologicas. - Google Patents

Preparacion de producto combinado para usarse en enfermedades inmunologicas.

Info

Publication number
MX9701385A
MX9701385A MX9701385A MX9701385A MX9701385A MX 9701385 A MX9701385 A MX 9701385A MX 9701385 A MX9701385 A MX 9701385A MX 9701385 A MX9701385 A MX 9701385A MX 9701385 A MX9701385 A MX 9701385A
Authority
MX
Mexico
Prior art keywords
immune diseases
therapy
combined preparation
compound
reduces
Prior art date
Application number
MX9701385A
Other languages
English (en)
Inventor
Martin Schonharting
Stefan Mullner
Peter Zabel
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of MX9701385A publication Critical patent/MX9701385A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una preparacion de producto combinado que comprende un compuesto que tiene una accion inhibidora de fosfodiesterasa y un compuesto que reduce el contenido de Ca2+ intracelular biologicamente efectivo, es apropiado para el tratamiento de enfermedades inmunologicas.
MX9701385A 1994-08-25 1995-08-07 Preparacion de producto combinado para usarse en enfermedades inmunologicas. MX9701385A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4430128A DE4430128A1 (de) 1994-08-25 1994-08-25 Kombinationspräparat mit immunsuppressiven, kardiovaskulären und cerebralen Wirkungen
PCT/EP1995/003125 WO1996005838A2 (de) 1994-08-25 1995-08-07 Kombinationspräparat zur anwendung bei immunologischen erkrankungen

Publications (1)

Publication Number Publication Date
MX9701385A true MX9701385A (es) 1997-05-31

Family

ID=6526515

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9701385A MX9701385A (es) 1994-08-25 1995-08-07 Preparacion de producto combinado para usarse en enfermedades inmunologicas.

Country Status (12)

Country Link
US (2) US5990103A (es)
EP (1) EP0777482B1 (es)
JP (1) JPH10504550A (es)
AT (1) ATE208620T1 (es)
AU (1) AU697311B2 (es)
DE (2) DE4430128A1 (es)
DK (1) DK0777482T3 (es)
ES (1) ES2162937T3 (es)
FI (1) FI970747L (es)
MX (1) MX9701385A (es)
PT (1) PT777482E (es)
WO (1) WO1996005838A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294350B1 (en) * 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
WO2000009133A1 (fr) * 1998-08-10 2000-02-24 Asahi Kasei Kogyo Kabushiki Kaisha Preparations orales, a liberation prolongee, a base de chlorhydrate de fasudil
US6368815B1 (en) * 1999-03-29 2002-04-09 Warner-Lambert Company Screening of molecules that inhibit human phosphodiesterase 4A produced by non-recombinant cell lines
CN100415743C (zh) * 1999-03-31 2008-09-03 韦尔纳利斯有限公司 嘧啶并[6,1-a] 异喹啉-4-酮衍生物
BR0111158A (pt) 2000-05-12 2004-04-06 Genzyme Corp Composto e sais fisiológicos do mesmo, método para tratar uma condição mediana por tnf-a em um paciente
US7470718B2 (en) * 2000-10-03 2008-12-30 Albert Einstein College Of Medicine Of Yeshiva University Method for treating a demyelinating condition
EP1426051B1 (en) * 2001-09-11 2008-07-16 Asahi Kasei Pharma Corporation Medicinal composition for prevention of or treatment for cerebrovascular disorder
KR100824491B1 (ko) * 2001-10-05 2008-04-22 콤비네이토릭스, 인코포레이티드 면역염증 질환의 치료를 위한 조합
DE10226420A1 (de) * 2002-06-13 2004-01-15 Eucro European Contract Research Gmbh & Co Kg Verfahren zur Behandlung der Artherosklerose
US8133903B2 (en) * 2003-10-21 2012-03-13 Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases
AU2003286555A1 (en) * 2002-10-22 2004-05-13 Harbor-Ucla Research And Education Institute Phosphodiester inhibitors and nitric oxide modulators for treating peyronie's disease, arteriosclerosis and other fibrotic diseases
AU2003291143A1 (en) * 2002-11-21 2004-06-18 Genzyme Corporation Combination of diamide derivatives and immunosuppressive agents for induction of immune tolerance
ES2363914T3 (es) * 2002-11-21 2011-08-19 Genzyme Corporation Utilización de un derivado de diamida para inhibir el rechazo crónico de un transplante.
US20040147534A1 (en) * 2003-01-23 2004-07-29 Foote Mary Ann Topical composition and method for treating occlusive wounds
US20040241234A1 (en) * 2003-06-02 2004-12-02 Alpharma, Inc. Controlled release press-coated formulations of water-soluble active agents
TW200517114A (en) * 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
WO2006054536A1 (ja) * 2004-11-16 2006-05-26 Nippon Shinyaku Co., Ltd. 尿路結石症治療剤
US20060269579A1 (en) * 2005-05-25 2006-11-30 Musculoskeletal Research Llc Compositions for treating osteoarthritis
US7767710B2 (en) 2005-05-25 2010-08-03 Calosyn Pharma, Inc. Method for treating osteoarthritis
CA2652773A1 (en) * 2006-05-22 2007-12-06 Combinatorx, Incorporated Methods and compositions for the treatment of diseases or conditions associated with increased c-reactive protein, interleukin-6, or interferon-gamma levels
US20090075955A1 (en) * 2007-09-19 2009-03-19 Combinatorx, Inc. Therapeutic regimens for the treatment of immunoinflammatory disorders
US20090163440A1 (en) * 2007-09-26 2009-06-25 Waddell David D Ion-Channel Regulator Compositions and Methods of Using Same
CA2709561A1 (en) * 2007-12-17 2009-06-25 Combinatorx, Incorporated Therapeutic regimens for the treatment of immunoinflammatory disorders
WO2009108383A2 (en) 2008-02-29 2009-09-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
US20110053961A1 (en) 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
US20140296263A1 (en) 2011-07-19 2014-10-02 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
CN104364255A (zh) 2012-04-13 2015-02-18 康塞特医药品有限公司 取代的黄嘌呤衍生物
EP3131554A1 (en) 2014-04-18 2017-02-22 Concert Pharmaceuticals Inc. Methods of treating hyperglycemia
EP3964212A4 (en) * 2019-04-30 2023-01-04 Generos Biopharma Ltd. COMPOUND FOR THE TREATMENT OF INFLAMMATORY AUTOIMMUNEAL DISEASES AND USE THEREOF

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63500243A (ja) * 1985-07-02 1988-01-28 キ−・ファ−マシュ−ティカルス・インコ−ポレ−テッド 慢性閉塞性肺疾患の治療方法および組成物
DE3604149A1 (de) * 1986-02-10 1987-08-13 Rentschler Arzneimittel Arzneimittelkombination
IL100195A0 (en) * 1990-11-30 1992-08-18 Hoechst Roussel Pharma Use of xanthines for the preparation of a medicament having immuno suppressing activity
EP0493682A3 (en) * 1990-11-30 1992-11-19 Hoechst-Roussel Pharmaceuticals Incorporated Use of xanthines for the preparation of a medicament effective for inhibiting the effects of allograft reaction in humans
IL99368A (en) * 1991-09-02 1996-01-19 Teva Pharma Preparations for the treatment of psoriasis and atopic dermatitis, which contain the result of xanthine
US5190972A (en) * 1992-01-27 1993-03-02 The University Of Melbourne Method of combatting cyclosporine organ toxicity with prostaglandin analogs
ES2191013T3 (es) * 1992-03-04 2003-09-01 Cell Therapeutics Inc Compuestos de xantina enantiomeros hidroxilados.
WO1993023082A1 (en) * 1992-05-13 1993-11-25 Alcon Laboratories, Inc. Topical ophthalmic compositions comprising a combination of calcium antagonists with known antiglaucoma agents
US5670506A (en) * 1993-04-05 1997-09-23 Cell Therapeutics, Inc. Halogen, isothiocyanate or azide substituted xanthines

Also Published As

Publication number Publication date
DE4430128A1 (de) 1996-02-29
EP0777482B1 (de) 2001-11-14
PT777482E (pt) 2002-04-29
US5990103A (en) 1999-11-23
FI970747A7 (fi) 1997-02-21
ATE208620T1 (de) 2001-11-15
AU3382995A (en) 1996-03-14
DK0777482T3 (da) 2002-02-18
EP0777482A1 (de) 1997-06-11
FI970747A0 (fi) 1997-02-21
US6337325B1 (en) 2002-01-08
DE59509848D1 (de) 2001-12-20
AU697311B2 (en) 1998-10-01
JPH10504550A (ja) 1998-05-06
ES2162937T3 (es) 2002-01-16
WO1996005838A2 (de) 1996-02-29
WO1996005838A3 (de) 1996-04-11
FI970747L (fi) 1997-02-21

Similar Documents

Publication Publication Date Title
MX9701385A (es) Preparacion de producto combinado para usarse en enfermedades inmunologicas.
ES2193337T3 (es) Utilizacion de sales de estroncio para el tratamiento de la artrosis.
ATE185548T1 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
BG100960A (bg) Дозирани форми с контролирано освобождаване на азитромицин
AU2160492A (en) Treatment of human diseases involving dysregulation or dysfunction of the nervous system
PL310476A1 (en) Application of lamotrigin in treating neuro-aids diseases
PT758241E (pt) Utilizacao de certos derivados de acido metanobisfosfonico para impedir o desprendimento de proteses e a migracao de proteses
PL323798A1 (en) Application of derivatives of vitamin d4 in treating skin diseases
DE69637178D1 (de) N-chlorphenylcarbamate enthaltendes arzneimittel sowie n-chlorphenylthiocarbamate zur hemmung des wachstums von viren
WO1998032428A3 (en) Compositions comprising choline and use of choline to treat endotoxic shock
GB9425730D0 (en) Compounds
BG102667A (en) Diosgenine-containing composition
BG105275A (en) Tan-1057 derivatives
ES2068714T3 (es) Derivados de pirimidina para aumentar la actividad antitumoral.
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
SE9601395D0 (sv) New therapeutic treatment 1
EP0744176A3 (en) Methods for inhibiting bone loss
CA2254533A1 (en) Treatment of pruritus
AR059965A2 (es) Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante
ES2046246T3 (es) Composicion terapeutica para combatir el sida.
ES2170807T3 (es) Uso de prostaglandinas para la fabricacion de un medicamento para la prevencion y el tratamiento de catarata secundaria.
MX9201258A (es) Compuestos para el tratamiento del cancer y procedimiento para su preparacion.
BR9701455A (pt) Uso de antagonistas de bradicinina para a preparaçao de medicamentos para o tratamento de doenças fibrogenéticas crônicas do fígado e doenças agudas do fígado
ZA944281B (en) Use of efaroxan and its derivatives for the preparation of a medicinal product intented for the treatment of parkinson's disease
ES2190499T3 (es) Uso de antagonistas de bradiquinina para la preparacion de medicamentos para el tratamiento y la prevencion de la enfermedad de alzheimer.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal